Diplomat Pharmacy, Inc. stock performance trend indicates that the stock price has rallied 21.23% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -43.73% . Looking at the past 52 week period, the stock price is down -38.99% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Diplomat Pharmacy, Inc. has a negative value of -54.64 compared to overall market performance.Diplomat Pharmacy, Inc. is having a Relative Strength Index of 63.08 which indicates the stock is not yet over sold or over bought based on the technical indicators.
Diplomat Pharmacy, Inc. (NYSE:DPLO) has climbed 5% in the past week and advanced 8.32% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 4.75% and the outperformance has advanced to 7.08% for the last 4 weeks period.
Company shares have received an average consensus rating of Hold for the current week Diplomat Pharmacy, Inc. (NYSE:DPLO) : On Friday heightened volatility was witnessed in Diplomat Pharmacy, Inc. (NYSE:DPLO) which led to swings in the share price. The stock opened for trading at $15.74 and hit $15.84 on the upside , eventually ending the session at $15.76, with a gain of 0.57% or 0.09 points. The heightened volatility saw the trading volume jump to 1,499,150 shares. The 52-week high of the share price is $38.94 and the company has a market cap of $1,056 million. The 52-week low of the share price is at $12.25 .
Company has reported several Insider transactions to the SEC, on Sep 16, 2016, Atheer A Kaddis (EVP of Sales & Strategic Align) sold 20,000 shares at 30.12 per share price.On Dec 8, 2015, Philip R Hagerman (Chairman and CEO) sold 2,300,000 shares at 33.60 per share price.On Dec 2, 2015, Gary W Kadlec (President) sold 30,000 shares at 35.08 per share price.
Diplomat Pharmacy Inc Last issued its quarterly earnings results on Feb 28, 2017. The company reported $0.08 EPS for the quarter, missing the analyst consensus estimate by $ -0.08. Analyst had a consensus of $0.16. The company had revenue of $1144.84 million for the quarter, compared to analysts expectations of $1157.38 million. The companys revenue was up 16.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.21 EPS.
Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. It aids in the dispensing, delivery, dosing and reimbursement of clinically intensive and specialty drugs. The company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat Pharmacy, Inc. is headquartered in Flint, Michigan.